At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bergen Psychosis Project 2 - The Bergen-Stavanger-Innsbruck-Trondheim Study
In Brief
A Phase 4 clinical trial evaluating Amisulpride, Aripiprazole, and 1 other intervention for Schizophrenia and Psychotic Disorders. Completed, enrolled 151 participants across 4 sites in 2 countries.
Detailed Summary
In the Bergen Psychosis Project 2 the antipsychotic drugs aripiprazole, amisulpride, and olanzapine will be compared head-to-head in patients with schizophrenia and related psychoses and followed for 12 months. The study is independent of the pharmaceutical industry, and in accordance with a pragmatic design a clinically relevant sample will be included with as few exclusion criteria as possible. The patients will be assessed repeatedly with regards to symptoms, side effects, and cognitive functioning, as well as laboratory parameters. The study hypothesis is that clinically meaningful differences among the drugs will be disclosed in a pragmatic design.
Study Details
Timeline
Interventions
Tablets, dose range 50-1200 mg/ day
Tablets, dose range 5-30 mg/ day
Tablets, dose range 2.5-20 mg/ day